In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients with some head/neck and lung cancers.
A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a DoD grant that will fund a clinical trial in patients with brain-metastatic breast cancer.
Roswell Park researchers have received recent grant awards totaling more than $15.4 million. These competitive awards include the first National Institutes of Health funding to study a new electronic tobacco device and a state grant supporting Roswell Park's work with the national Cancer Moonshot.
Roswell Park researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a chemotherapy commonly prescribed for patients with advanced liver cancer.
Researchers from Roswell Park have developed a new bioinformatics-based approach for monitoring key changes in cancer cells — a data-driven method that might help to enhance and personalize cancer treatment.
A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.
Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.
With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.
A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.
In a new article in JNCI reporting the first known prognostic marker for triple-negative breast cancer, researchers provide evidence that a widely used breast cancer drug, tamoxifen, may be effective against this notoriously aggressive disease subtype.
A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo reports that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.
New research from Roswell Park Comprehensive Cancer Center reports that timing of radiation treatments can significantly reduce severity of mucositis and its related impacts.
Final results from the first U.S. clinical study of CIMAvax-EGF show that this Cuban immunotherapy is safe and showed promising efficacy as part of a treatment combination with nivolumab in patients with advanced non-small cell lung cancer.
Several Roswell Park Comprehensive Cancer Center experts were invited to highlight research and best practices during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas.
Roswell Park Comprehensive Cancer Center has been recognized as one of America’s Best Employers for Diversity 2019. The Buffalo cancer center was ranked 67th among 500 employers and 8th among the 30 employers within the health care sector to be named to the list, which is based on employee surveys.
The largest study to date to compare exposure to toxicants among users of electronic cigarettes, smokers and nonsmokers has been completed, suggesting possible benefits for smokers who switch completely to electronic cigarettes
New research out of Roswell Park Comprehensive Cancer Center shows that cancer patients who exercise regularly both before and after their diagnosis are significantly more likely to survive than those who are sedentary, adding to the growing body of evidence that physical activity is an important part of a cancer prevention and treatment strategy. The results were published in a recent issue of the journal Cancer Causes & Control.
Pain after surgery can be effectively managed with minimal or no opioids, according to research conducted at Roswell Park Comprehensive Cancer Center and published today in JAMA Network Open. A two-year study by a multidisciplinary team of surgeons and other cancer specialists shows that the amount of opioid medications prescribed after surgery can be drastically reduced without negatively affecting pain scores, postoperative complications or patient requests for additional
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. The findings were presented at the Society for Neuro-Oncology Annual Meeting in New Orleans.
In an effort to compile and summarize the latest knowledge about these immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published online Nov. 21 by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.
A new derivative of a compound found in the bark of a rare Chinese tree has powerful anticancer properties and a low toxicity profile, according to new research from a Roswell Park Comprehensive Cancer Center published in the Journal of Experimental & Clinical Cancer Research.
Governor Andrew M. Cuomo today announced Buffalo-based Roswell Park Comprehensive Cancer Center has formed the Innovative Immunotherapy Alliance S.A., the first-ever biotech venture between the U.S. and Cuba.
Through a grant award provided by the Cancer MoonshotSM, Roswell Park Comprehensive Cancer Center will support and advance some of the nation’s most ambitious cancer research projects.
The expertise of two regional research teams has earned a federal grant of nearly $20 million to create the nation’s first program dedicated to the study of flavored tobacco.
A team led by Marc Ernstoff, MD, of Roswell Park Comprehensive Cancer Center found that a drug complex containing IL-15 is both safe and well tolerated in patients with advanced solid tumors.
A new Roswell Park/Stony Brook Children's Hospital study reports striking findings: that young users of newer “pod” e-cigarette devices are absorbing nicotine at levels approaching nicotine exposure from traditional combustible cigarettes.
A Roswell Park-led research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target. Their findings were published in the journal Nature Communications.
A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography (CT) imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine — before surgery — whether the tumor is benign or malignant.
y-two local high school students participated in a unique career development program at Roswell Park Comprehensive Cancer Center this summer. The Buffalo Healthcare Exploration (BHE) program
Research to be presented at the ASCO 2018 Annual Meeting suggests that a new treatment combination can extend survival for many patients with advanced colorectal cancer and that its efficacy compares favorably to single-agent approaches.
Roswell Park Comprehensive Cancer Center researchers have identified significant differences in the immune microenvironment of breast cancer tumors between African-American and white women, shedding light on the ways in which race can influence cancer development and outcomes. The findings, to be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, are based on based on a comprehensive review of data from The Cancer Genome Atlas.
Presenting new data at ASCO 2018, collaborators from Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC report that the combination of SurVaxM plus standard therapy for patients with glioblastoma appears to be safe, effective and worthy of further evaluation.
Roswell Park Comprehensive Cancer Center researchers have identified epigenetic differences in the breast cancer tumors of African-American women and women of European descent, shedding light on one mechanism by which race may influence the way breast cancer develops.
Roswell Park Comprehensive Cancer Center researchers have once again identified a link between physical inactivity and an increased risk of mortality among cancer patients, emphasizing the importance of regular exercise as therapy for cancer patients both during and after treatment.
Roswell Park Comprehensive Cancer Center researchers have identified a potential key player promoting cancer progression through changes in the cell environment that are conducive to metastasis.
Roswell Park Comprehensive Cancer Center researchers have identified the histone H2AX as a potential biomarker for breast cancer — a determination that could also help predict how a patient will respond to radiation therapy.
Roswell Park Comprehensive Cancer Center researchers have found that the effect of a key gene driving an aggressive, recurrent and often incurable form of prostate cancer is dose-dependent, opening new avenues for therapies that overcome resistance to treatment of advanced disease.
New research out of Roswell Park Comprehensive Cancer Center and The Ohio State University has identified rare variants in a number of novel genes that may help improve risk prediction and prognosis for patients undergoing BMT.
In new research published in Nature, a team led by Subhamoy Dasgupta, PhD, of Roswell Park Comprehensive Cancer Center reports its identification of two key proteins involved in glucose metabolism that could be targeted to prevent breast cancer metastasis and recurrence.
New research from Roswell Park Comprehensive Cancer Center and MimiVax LLC, published in Clinical Cancer Research, shows that survivin — one of the most commonly occurring molecules in cancer cells — may be an attractive target for a broad range of immunotherapy approaches, including CAR T.
More than a dozen Roswell Park Comprehensive Cancer Center clinicians and researchers have been invited to present new findings at the 71st annual Cancer Symposium of the Society of Surgical Oncology (SSO).
Trust among surgical teams can be measured using EEG activity, according to new Roswell Park Comprehensive Cancer Center research published in Scientific Reports. The research team used brain activity patterns to objectively assess the level of trust between mentor and trainee during robot-assisted surgery.
Roswell Park Comprehensive Cancer Center has been officially approved to administer an FDA-approved CAR T-cell therapy, Yescarta, to lymphoma patients.
Using data from a large ovarian cancer registry, a research team from Roswell Park Comprehensive Cancer Center uncovered a link between testicular cancer and familial ovarian cancer that may be attributable to genetic factors on the X chromosome.
The second location of The Healthy Scratch opened on Roswell Park’s campus. The grab-and-go café provides patients, visitors and employees with a new option for clean eating – and for foods and juices that may help to keep cancer at bay.
Roswell Park Comprehensive Cancer Center-led research teams have identified a direct association between physical inactivity and two different types of cancer: lung cancer and head/neck cancer — adding to a growing list of cancers linked to sedentary lifestyles.
The American College of Nuclear Medicine (ACNM) has named Alan Klitzke, MD, FACNM, as its 47th president.
A team from Roswell Park Cancer Institute has discovered a unique population of normal stem cells that may enable prostate cancer relapse. These findings may point the way toward strategies for treating or preventing prostate cancer recurrence.
In a new study in the journal Nature Communications, a research team from Roswell Park Cancer Institute reports their discovery of a major mechanism by which cells regulate the tumor suppressor p53, opening up new avenues for cancer research and treatment.
Dr. Eunice Wang was invited to discuss results of a phase II clinical trial of crenolanib for adults with AML at the ASH 2017 annual meeting, and Dr. Kara Kelly, senior author of an oral abstract on outcomes disparities among children and adolescents with Hodgkin lymphoma.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right